TAKEDA PHARM CO LTD (TKPHF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Jun 25, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TKPHF SEC filings page.
TAKEDA PHARM CO LTD (TKPHF) reported $30.6B in revenue for fiscal year 2025, up 8.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
TAKEDA PHARM CO LTD does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
TAKEDA PHARM CO LTD scores 1.33, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
TAKEDA PHARM CO LTD passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, TAKEDA PHARM CO LTD generates $9.80 in operating cash flow ($7.1B OCF vs $720.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
TAKEDA PHARM CO LTD earns $2.49 in operating income for every $1 of interest expense ($2.3B vs $916.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
TAKEDA PHARM CO LTD generated $30.6B in revenue in fiscal year 2025. This represents an increase of 8.4% from the prior year.
TAKEDA PHARM CO LTD's EBITDA was $2.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 58.0% from the prior year.
TAKEDA PHARM CO LTD reported $720.0M in net income in fiscal year 2025. This represents a decrease of 24.4% from the prior year.
TAKEDA PHARM CO LTD earned $0.45 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 25.6% from the prior year.
Cash & Balance Sheet
TAKEDA PHARM CO LTD generated $5.7B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 59.7% from the prior year.
TAKEDA PHARM CO LTD held $2.6B in cash against $26.5B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
TAKEDA PHARM CO LTD's gross margin was 65.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.0 percentage points from the prior year.
TAKEDA PHARM CO LTD's operating margin was 7.5% in fiscal year 2025, reflecting core business profitability. This is up 2.5 percentage points from the prior year.
TAKEDA PHARM CO LTD's net profit margin was 2.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.0 percentage points from the prior year.
TAKEDA PHARM CO LTD's ROE was 1.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the prior year.
Capital Allocation
TAKEDA PHARM CO LTD invested $4.9B in research and development in fiscal year 2025. This represents an increase of 0.9% from the prior year.
TAKEDA PHARM CO LTD spent $346.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 2113.0% from the prior year.
TAKEDA PHARM CO LTD invested $1.3B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 15.5% from the prior year.
TKPHF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.6B+8.4% | $28.2B-7.1% | $30.3B+3.2% | $29.4B+1.7% | $28.9B-5.5% | $30.6B+61.5% | $18.9B+13.7% | $16.7B+7.2% | $15.5B |
| Cost of Revenue | $10.5B+11.7% | $9.4B+0.7% | $9.4B+2.8% | $9.1B+1.4% | $9.0B-11.3% | $10.1B+72.1% | $5.9B+26.1% | $4.7B-6.9% | $5.0B |
| Gross Profit | $20.0B+6.7% | $18.8B-10.5% | $21.0B+3.4% | $20.3B+1.8% | $19.9B-2.7% | $20.5B+56.8% | $13.1B+8.8% | $12.0B+14.0% | $10.5B |
| R&D Expenses | $4.9B+0.9% | $4.8B+1.2% | $4.8B+10.1% | $4.3B+5.1% | $4.1B-10.0% | $4.6B+37.6% | $3.3B+8.6% | $3.1B+9.3% | $2.8B |
| Operating Income | $2.3B+61.4% | $1.4B-61.7% | $3.7B-2.6% | $3.8B-17.6% | $4.6B+393.1% | $933.8M-56.5% | $2.1B-5.7% | $2.3B+62.7% | $1.4B |
| EBITDA | $2.3B+58.0% | $1.5B-60.5% | $3.7B-2.3% | $3.8B-19.3% | $4.7B+235.0% | $1.4B-35.0% | $2.2B-10.5% | $2.4B+68.9% | $1.4B |
| Interest Expense | $916.0M+15.9% | $790.5M-10.3% | $881.2M-12.6% | $1.0B-14.7% | $1.2B-14.7% | $1.4B+218.5% | $435.1M+360.4% | $94.5M+39.3% | $67.9M |
| Income Tax | $446.6Mn/m | -$604.5M-238.2% | $437.3M-26.7% | $596.2Mn/m | -$89.8Mn/m | -$976.9Mn/m | -$67.5M-123.5% | $287.2M+14.9% | $249.8M |
| Net Income | $720.0M-24.4% | $952.7M-60.1% | $2.4B+26.1% | $1.9B-44.3% | $3.4B+726.2% | $411.4M-66.3% | $1.2B-30.6% | $1.8B+70.6% | $1.0B |
| EPS (Basic) | $0.46-25.1% | $0.61-60.4% | $1.54+27.0% | $1.21-44.3% | $2.18+723.7% | $0.26 | $1.27-43.6% | $2.25+70.6% | $1.32 |
| EPS (Diluted) | $0.45-25.6% | $0.60-60.4% | $1.52+26.6% | $1.20-44.4% | $2.16+722.4% | $0.26 | $1.26-43.5% | $2.24+70.4% | $1.31 |
| Diluted Shares (Avg) | 1.61B+1.6% | 1.58B+0.7% | 1.57B-0.5% | 1.58B+0.2% | 1.57B+0.5% | 1.57B | 967M+22.9% | 787M+0.1% | 786M |
Not reported in any period shown, so not listed: SG&A Expenses.
TKPHF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $95.1B-4.9% | $99.9B-5.0% | $105.1B-3.1% | $108.5B-7.0% | $116.7B-2.1% | $119.2B-4.3% | $124.6B+222.3% | $38.7B | N/A |
| Current Assets | $16.8B-0.6% | $16.9B-6.3% | $18.1B-15.4% | $21.4B-12.9% | $24.5B+6.8% | $23.0B-15.1% | $27.0B+166.2% | $10.2B | N/A |
| Cash & Equivalents | $2.6B-15.1% | $3.0B-24.7% | $4.0B-42.6% | $7.0B-19.9% | $8.7B+47.3% | $5.9B-6.5% | $6.3B+128.7% | $2.8B-3.3% | $2.9B |
| Inventory | $8.1B+1.5% | $8.0B+7.7% | $7.4B+5.8% | $7.0B+3.1% | $6.8B-3.5% | $7.1B-15.0% | $8.3B+314.4% | $2.0B | N/A |
| Accounts Receivable | $4.7B+7.1% | $4.4B-9.6% | $4.9B-14.7% | $5.7B-19.0% | $7.1B+0.6% | $7.0B+5.0% | $6.7B+69.4% | $4.0B | N/A |
| Goodwill | $35.5B-0.7% | $35.8B-0.9% | $36.1B-0.6% | $36.3B-0.5% | $36.5B-2.3% | $37.3B-2.6% | $38.3B+295.3% | $9.7B | N/A |
| Total Liabilities | $48.8B-5.8% | $51.8B-9.5% | $57.3B-7.2% | $61.7B-11.8% | $69.9B-7.1% | $75.3B-3.2% | $77.8B+295.3% | $19.7B | N/A |
| Current Liabilities | $16.7B+9.3% | $15.3B-18.2% | $18.7B+5.8% | $17.7B+10.2% | $16.0B-20.8% | $20.2B-12.3% | $23.1B+232.2% | $6.9B | N/A |
| Non-Current Liabilities | $32.1B-12.2% | $36.5B-5.3% | $38.6B-12.4% | $44.0B-18.3% | $53.9B-2.1% | $55.0B+0.6% | $54.7B+329.8% | $12.7B | N/A |
| Long-Term Debt | $26.5B-10.6% | $29.6B-2.8% | $30.5B-10.7% | $34.1B-18.2% | $41.7B-0.5% | $41.9B-2.7% | $43.1B+364.0% | $9.3B | N/A |
| Total Equity | $46.3B-3.8% | $48.1B+0.5% | $47.9B+2.3% | $46.8B+0.1% | $46.8B+6.5% | $43.9B-6.2% | $46.8B+148.9% | $18.8B+7.5% | $17.5B |
| Retained Earnings | $7.9B-13.9% | $9.2B-20.8% | $11.6B-4.7% | $12.2B-10.7% | $13.7B+7.1% | $12.7B-11.6% | $14.4B-1.7% | $14.7B | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
TKPHF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.1B+48.9% | $4.7B-35.6% | $7.4B-20.4% | $9.2B+1.2% | $9.1B+46.7% | $6.2B+109.9% | $3.0B-16.6% | $3.6B+51.7% | $2.3B |
| Depreciation & Amortization | $30.3M-39.0% | $49.7M+184.7% | $17.5M+343.1% | $3.9M-96.2% | $103.0M-78.1% | $471.2M+3516.8% | $13.0M-90.5% | $137.5M+348.4% | $30.7M |
| Capital Expenditures | $1.3B+15.5% | $1.2B+9.5% | $1.1B+4.4% | $1.0B+0.9% | $1.0B-14.9% | $1.2B+68.4% | $701.8M+11.2% | $630.9M+14.0% | $553.5M |
| Free Cash Flow | $5.7B+59.7% | $3.6B-43.2% | $6.3B-23.5% | $8.2B+1.2% | $8.1B+61.2% | $5.0B+122.7% | $2.3B-22.6% | $2.9B+63.3% | $1.8B |
| Investing Cash Flow | -$2.4Bn/m | -$3.1Bn/m | -$4.6Bn/m | -$1.6B-145.9% | $3.6B+31.0% | $2.7Bn/m | -$25.6Bn/m | -$878.9Mn/m | -$5.9B |
| Financing Cash Flow | -$5.0Bn/m | -$2.3Bn/m | -$5.3Bn/m | -$8.8Bn/m | -$9.8Bn/m | -$9.3B-135.1% | $26.6Bn/m | -$3.1B-218.1% | $2.6B |
| Dividends Paid | $2.0B+6.3% | $1.9B-9.8% | $2.1B-9.9% | $2.3B-8.8% | $2.6B-2.5% | $2.6B+103.5% | $1.3B-3.3% | $1.3B+5.1% | $1.3B |
| Share Buybacks | $346.4M+2113.0% | $15.7M-92.3% | $203.9M-68.8% | $654.2M+3279.8% | $19.4M-96.1% | $490.6M+4532.7% | $10.6M-97.3% | $391.2M+88.5% | $207.5M |
Not reported in any period shown, so not listed: Stock-Based Compensation.
TKPHF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.5%-1.0pp | 66.5%-2.6pp | 69.1%+0.1pp | 69.0%+0.1pp | 68.9%+2.0pp | 66.9%-2.0pp | 68.9%-3.1pp | 72.0%+4.2pp | 67.7% |
| Operating Margin | 7.5%+2.5pp | 5.0%-7.2pp | 12.2%-0.7pp | 12.9%-3.0pp | 15.9%+12.9pp | 3.0%-8.3pp | 11.3%-2.3pp | 13.7%+4.7pp | 9.0% |
| Net Margin | 2.4%-1.0pp | 3.4%-4.5pp | 7.9%+1.4pp | 6.5%-5.3pp | 11.8%+10.4pp | 1.3%-5.1pp | 6.5%-4.1pp | 10.6%+3.9pp | 6.6% |
| Return on Equity | 1.6%-0.4pp | 2.0%-3.0pp | 5.0%+0.9pp | 4.0%-3.2pp | 7.3%+6.3pp | 0.9%-1.7pp | 2.6%-6.8pp | 9.4%+3.5pp | 5.9% |
| Return on Assets | 0.8%-0.2pp | 0.9%-1.3pp | 2.3%+0.5pp | 1.8%-1.2pp | 2.9%+2.6pp | 0.4%-0.6pp | 1.0%-3.6pp | 4.5% | N/A |
| Current Ratio | 1.01-0.1x | 1.11+0.1x | 0.97-0.2x | 1.21-0.3x | 1.53+0.4x | 1.130.0x | 1.17-0.3x | 1.46 | N/A |
| Debt-to-Equity | 0.570.0x | 0.620.0x | 0.64-0.1x | 0.73-0.2x | 0.89-0.1x | 0.950.0x | 0.92+0.4x | 0.49 | N/A |
| Liabilities-to-Equity | 1.050.0x | 1.08-0.1x | 1.20-0.1x | 1.32-0.2x | 1.50-0.2x | 1.71+0.1x | 1.66+0.6x | 1.05 | N/A |
| Asset Turnover | 0.320.0x | 0.280.0x | 0.290.0x | 0.270.0x | 0.250.0x | 0.26+0.1x | 0.15-0.3x | 0.43 | N/A |
| FCF Margin | 18.7%+6.0pp | 12.7%-8.1pp | 20.8%-7.2pp | 28.0%-0.1pp | 28.1%+11.6pp | 16.5%+4.5pp | 12.0%-5.6pp | 17.6%+6.0pp | 11.5% |
Where TAKEDA PHARM CO LTD Ranks
Frequently Asked Questions
What is TAKEDA PHARM CO LTD's annual revenue?
TAKEDA PHARM CO LTD (TKPHF) reported $30.6B in total revenue for fiscal year 2025. This represents a 8.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is TAKEDA PHARM CO LTD's revenue growing?
TAKEDA PHARM CO LTD (TKPHF) revenue grew by 8.4% year-over-year, from $28.2B to $30.6B in fiscal year 2025.
Is TAKEDA PHARM CO LTD profitable?
Yes, TAKEDA PHARM CO LTD (TKPHF) reported a net income of $720.0M in fiscal year 2025, with a net profit margin of 2.4%.
What is TAKEDA PHARM CO LTD's EBITDA?
TAKEDA PHARM CO LTD (TKPHF) had EBITDA of $2.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does TAKEDA PHARM CO LTD have?
As of fiscal year 2025, TAKEDA PHARM CO LTD (TKPHF) had $2.6B in cash and equivalents against $26.5B in long-term debt.
What is TAKEDA PHARM CO LTD's gross margin?
TAKEDA PHARM CO LTD (TKPHF) had a gross margin of 65.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is TAKEDA PHARM CO LTD's operating margin?
TAKEDA PHARM CO LTD (TKPHF) had an operating margin of 7.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is TAKEDA PHARM CO LTD's net profit margin?
TAKEDA PHARM CO LTD (TKPHF) had a net profit margin of 2.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is TAKEDA PHARM CO LTD's return on equity (ROE)?
TAKEDA PHARM CO LTD (TKPHF) has a return on equity of 1.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is TAKEDA PHARM CO LTD's free cash flow?
TAKEDA PHARM CO LTD (TKPHF) generated $5.7B in free cash flow during fiscal year 2025. This represents a 59.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TAKEDA PHARM CO LTD's operating cash flow?
TAKEDA PHARM CO LTD (TKPHF) generated $7.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are TAKEDA PHARM CO LTD's total assets?
TAKEDA PHARM CO LTD (TKPHF) had $95.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are TAKEDA PHARM CO LTD's capital expenditures?
TAKEDA PHARM CO LTD (TKPHF) invested $1.3B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does TAKEDA PHARM CO LTD spend on research and development?
TAKEDA PHARM CO LTD (TKPHF) invested $4.9B in research and development during fiscal year 2025.
What is TAKEDA PHARM CO LTD's current ratio?
TAKEDA PHARM CO LTD (TKPHF) had a current ratio of 1.01 as of fiscal year 2025, which is considered adequate.
What is TAKEDA PHARM CO LTD's debt-to-equity ratio?
TAKEDA PHARM CO LTD (TKPHF) had a debt-to-equity ratio of 0.57 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is TAKEDA PHARM CO LTD's liabilities-to-equity ratio?
TAKEDA PHARM CO LTD (TKPHF) had a liabilities-to-equity ratio of 1.05 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is TAKEDA PHARM CO LTD's return on assets (ROA)?
TAKEDA PHARM CO LTD (TKPHF) had a return on assets of 0.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is TAKEDA PHARM CO LTD's P/E ratio?
TAKEDA PHARM CO LTD (TKPHF) trades at 91.4x earnings, its market capitalization divided by $720.0M net income, FY2025. The market capitalization is $65.8B as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is TAKEDA PHARM CO LTD's price-to-sales ratio?
TAKEDA PHARM CO LTD (TKPHF) trades at 2.2x sales, its market capitalization divided by $30.6B revenue, FY2025. The market capitalization is $65.8B as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is TAKEDA PHARM CO LTD's Altman Z-Score?
TAKEDA PHARM CO LTD (TKPHF) has an Altman Z-Score of 1.33, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is TAKEDA PHARM CO LTD's Piotroski F-Score?
TAKEDA PHARM CO LTD (TKPHF) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are TAKEDA PHARM CO LTD's earnings high quality?
TAKEDA PHARM CO LTD (TKPHF) has an earnings quality ratio of 9.80x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can TAKEDA PHARM CO LTD cover its interest payments?
TAKEDA PHARM CO LTD (TKPHF) has an interest coverage ratio of 2.49x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.